Principal Financial Group Inc. Sells 129,130 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Principal Financial Group Inc. lessened its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 35.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 238,605 shares of the medical equipment provider's stock after selling 129,130 shares during the period. Principal Financial Group Inc. owned about 0.34% of Lantheus worth $26,187,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in LNTH. AlphaCentric Advisors LLC bought a new position in Lantheus in the 3rd quarter valued at approximately $988,000. Moloney Securities Asset Management LLC bought a new position in shares of Lantheus in the 3rd quarter valued at $1,066,000. Citizens National Bank Trust Department lifted its stake in shares of Lantheus by 2.4% in the 3rd quarter. Citizens National Bank Trust Department now owns 12,798 shares of the medical equipment provider's stock valued at $1,405,000 after acquiring an additional 298 shares during the last quarter. Van ECK Associates Corp grew its position in Lantheus by 58.6% during the 3rd quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider's stock worth $6,469,000 after acquiring an additional 21,604 shares during the last quarter. Finally, Harbor Capital Advisors Inc. increased its holdings in Lantheus by 56.0% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 128,913 shares of the medical equipment provider's stock worth $14,148,000 after purchasing an additional 46,262 shares in the last quarter. Institutional investors own 99.06% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on LNTH shares. JMP Securities cut their price target on Lantheus from $125.00 to $112.00 and set a "market outperform" rating on the stock in a research note on Thursday, November 7th. Redburn Atlantic assumed coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They set a "buy" rating and a $175.00 target price on the stock. Truist Financial restated a "buy" rating and issued a $120.00 price target (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. StockNews.com upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a report on Friday, November 8th. Finally, B. Riley increased their price objective on Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a report on Thursday, July 25th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $122.50.

Lantheus Price Performance

Shares of Lantheus stock traded down $2.91 on Wednesday, hitting $82.24. 939,934 shares of the company's stock traded hands, compared to its average volume of 1,002,677. The company has a fifty day moving average of $106.48 and a two-hundred day moving average of $96.39. Lantheus Holdings, Inc. has a one year low of $50.20 and a one year high of $126.89. The company has a market capitalization of $5.72 billion, a price-to-earnings ratio of 13.65 and a beta of 0.51.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.